FierceBiotech

OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer

OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer BOTHELL, Wash. and VANCOUVER, British ...
FierceBiotech

OncoGenex Announces that the Borealis-2™ Clinical Trial of OGX-427 in Previously Treated Metastatic Bladder Cancer is now Open for Enrollment

The OGX-427 ORCA™ Program Continues to Expand with Patient Enrollment Now Open for Second Phase 2 Trial of OGX-427 in Advanced Bladder Cancer Borealis-2 will randomize approximately 200 patients to ...
ascopubs.org

Borealis-2: A randomized phase II study of OGX-427 (apatorsen) plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial cancer (mUC) (Hoosier Cancer ...

Long-term incidence of venous thromboembolic events following cystectomy: A population-based analysis. This is an ASCO Meeting Abstract from the 2017 Genitourinary Cancers Symposium. This abstract ...
ascopubs.org

The Borealis-2 clinical trial: A randomized phase 2 study of OGX-427 (Apatorsen) plus docetaxel versus docetaxel alone in relapsed/refractory metastatic urothelial cancer.

A phase I/II multi-center study of intravesical nanoparticle albumin-bound rapamycin (ABI-009) in the treatment of BCG refractory non-muscle invasive bladder cancer. This is an ASCO Meeting Abstract ...